Compare CCCC & MATV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCCC | MATV |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Paper |
| Sector | Health Care | Basic Materials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.7M | 440.9M |
| IPO Year | 2020 | 1996 |
| Metric | CCCC | MATV |
|---|---|---|
| Price | $3.70 | $8.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $12.20 | N/A |
| AVG Volume (30 Days) | ★ 4.0M | 472.3K |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 4.24% |
| EPS Growth | ★ 16.45 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $35,947,000.00 | N/A |
| Revenue This Year | N/A | $2.97 |
| Revenue Next Year | N/A | $4.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1.02 | N/A |
| 52 Week Low | $1.69 | $6.17 |
| 52 Week High | $5.17 | $15.48 |
| Indicator | CCCC | MATV |
|---|---|---|
| Relative Strength Index (RSI) | 43.11 | 52.59 |
| Support Level | $2.10 | $7.89 |
| Resistance Level | $3.89 | $8.32 |
| Average True Range (ATR) | 0.37 | 0.39 |
| MACD | -0.10 | 0.08 |
| Stochastic Oscillator | 16.47 | 71.43 |
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Mativ Holdings Inc is a leader in specialty materials, solving its customers' complex challenges by engineering bold, inventive solutions that connect, protect, and purify the world. The company operates in two segments, namely Filtration & advanced Materials, focused on filtration media and components, developed films, coating and converting solutions, and extruded mesh products, and (2) Sustainable & Adhesive Solutions (SAS), focused on tapes, labels, liners, specialty paper, packaging, and healthcare solutions.